Ciro Celsa

27PUBLICATIONS
119CO-AUTHORS
Haematological tumoursPredictive and prognostic markersBehavioural epidemiologyRespiratory diseasesTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jan 28, 2026
Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.

Fabio Melandro, Leonardo Centonze, Ciro Celsa

|Feb 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.

Ciro Celsa, Grazia Pennisi, Adele Tulone

|Nov 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death.

Giuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia

|Aug 29, 2024
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.

Ciro Celsa, Giacomo E M Rizzo, Gabriele Di Maria

|Jul 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi

|Apr 05, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.

David J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi

Pageof 5

Frequent Collaborators

13 joint publications

Giuseppe Cabibbo

7 joint publications

Calogero Cammà

4 joint publications

Fabio Marra

4 joint publications

Paolo Giuffrida